Release Date: 30-Aug-2023
Blincyto is a bispecific antibody developed by Amgen that was authorized in 2014 for the treatment of precursor B-cell acute lymphoblastic leukemia. The drug has since gained four additional approvals for use in various subsets of individuals with precursor B-cell acute lymphoblastic leukemia; this expansion of Blincyto's target population base has resulted in increased sales. Blincyto's annual sales in 2022 was reported as US$ 581 million. Furthermore, by the first half of 2023, the sale of Blincyto had already exceeded half of this figure, with a value of US$ 400 million. With sales totaling US$ 145 million in 2023, the US retained its position as the leading contributor to this sales value. This increase in Blincyto sales has been attributed to the increasing drug adoption as well as a higher net selling price.
Download Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023
Download US Bispecific Antibody Market and Clinical Pipeline Insight 2028